Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | TK1 | P04183 | 3/20 | 0.42 |
| ▸ | TK2 | O00142 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16378861 | 0.79 | LMNA (0.49) | LMNASMN1; SMN2ADRB1DNMT1ALOX12 | |
| SCHEMBL29388908 | 0.79 | LMNA (0.49) | LMNASMN1; SMN2ADRB1DNMT1ALOX12 | |
| SCHEMBL6261479 | 0.78 | LMNA (0.46) | LMNASMN1; SMN2ADRB1DNMT1ALOX12 | |
| SCHEMBL288668 | 0.76 | LMNA (0.42) | LMNASMN1; SMN2DNMT1CYP3A4TSHR | |
| SCHEMBL6910650 | 0.76 | LMNA (0.44) | LMNASMN1; SMN2ADRB1DNMT1ALOX12 | |
| SCHEMBL5705312 | 0.76 | LMNA (0.46) | LMNASMN1; SMN2ADRB1DNMT1ALOX12 | |
| SCHEMBL23892752 | 0.73 | LMNA (0.45) | LMNASMN1; SMN2ADRB1DNMT1ALOX12 | |
| SCHEMBL4214653 | 0.71 | LMNA (0.49) | LMNASMN1; SMN2ADRB1DNMT1ALOX12 | |
| SCHEMBL4214655 | 0.71 | LMNA (0.49) | LMNASMN1; SMN2ADRB1DNMT1ALOX12 | |
| SCHEMBL5590794 | 0.71 | LMNA (0.44) | LMNASMN1; SMN2ADRB1DNMT1ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1137764-B1 | NEW MEDICAL USE OF GENE AND VECTOR ENCODING A MULTISUBSTRATE DEOXYRIBONUCLEOSIDASE | ZGENE AS (DK) | 2005-03-02 | — | — | EP | disclosed |
| US-6582947-B1 | Nucleotide sequences coding enzymatic polypeptide for use in the virus treatment of cancer and viral infection | BIO VICI (CH) | 2003-06-24 | — | — | US | disclosed |
| US-20030013880-A1 | Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers | APOTEX PHARMACHEM INC (CA) | 2003-01-16 | — | — | US | disclosed |
| US-6335339-B1 | PREVENTING HEPATITIS B INFECTION WITH VIRICIDE | SCRIPTGEN PHARMACEUTICALS, INC. | 2002-01-01 | — | — | US | disclosed |
| EP-1137764-A1 | NEW MEDICAL USE OF GENE AND VECTOR ENCODING A MULTISUBSTRATE DEOXYRIBONUCLEOSIDASE | Biovici (CH) | 2001-10-04 | — | — | EP | disclosed |
| EP-1053230-A1 | TRIAZINE ANTIVIRAL COMPOUNDS | Scriptgen Pharmaceuticals, Inc. (US) | 2000-11-22 | — | — | EP | disclosed |
| WO-2000036099-A1 | NEW MEDICAL USE OF GENE AND VECTOR ENCODING A MULTISUBSTRATE DEOXYRIBONUCLEOSIDASE | BIOVICI (CH) | 2000-06-22 | — | — | WO | disclosed |
| EP-0979650-A1 | ANTIVIRAL AGENTS | MITSUBISHI CHEMICAL CORPORATION (JP) | 2000-02-16 | — | — | EP | disclosed |
| EP-0970074-A1 | METHOD AND COMPOSITIONS FOR THE SYNTHESIS OF DIOXOLANE NUCLEOSIDES WITH $g(b)-CONFIGURATION | BIOCHEM PHARMA INC (CA) | 2000-01-12 | — | — | EP | disclosed |
| WO-1999036410-A9 | TRIAZINE ANTIVIRAL COMPOUNDS | SCRIPTGEN PHARM INC (US) | 1999-09-30 | — | — | WO | disclosed |
| WO-1999036410-A1 | TRIAZINE ANTIVIRAL COMPOUNDS | SCRIPTGEN PHARMACEUTICALS, INC. (US) | 1999-07-22 | — | — | WO | disclosed |
| WO-1997021706-A1 | METHOD AND COMPOSITIONS FOR THE SYNTHESIS OF DIOXOLANE NUCLEOSIDES WITH β-CONFIGURATION | BIOCHEM PHARMA INC. (CA) | 1997-06-19 | — | — | WO | disclosed |
| EP-0635026-A1 | NOVEL LIPOPHILIC OLIGOPEPTIDES WITH IMMUNOMODULATING ACTIVITY | BIOCHEM PHARMA INC (CA) | 1995-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013880-A1 | Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers | SLC29A1, NUDT1, SLC28A1 | LMNA 1280/4885SMN1; SMN2 664/4885ADRB1 1091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.